Cytokinetics (CYTK) Presents Non-Clincial Data Relating to GSK-923295 at AACR-NCI-EORTC Int. Conference
More News related to CYTK
- Cytokinetics (CYTK) Tops Q4 EPS by 1c
- Cytokinetics, Incorporated Reports Fourth Quarter and Year End 2009 Financial Results
- Trading Radar for 02/03: Cisco (CSCO), ON Semi (ONNN), Visa (V), Novellus (NVLS), Monster Worldwide (MWW) Report
- Cytokinetics to Present at BIO CEO and Investor Conference
- Cytokinetics to Announce Fourth Quarter and Year End Results On February 3, 2010
More News related to Corporate News
- S&P Announces Change to US Index: TSRA for FIF
- RealNetworks (RNWK) and MTV Networks (VIA-B) to Split Off Joint Venture Rhapsody
- Watts Water (WTS) Board Approves Restructuring Program; Shutting Down 3 Plants, Cutting 95 Jobs
- Transcept Pharmaceuticals (TSPT) Granted U.S. Patent Covering Intermezzo Formulation
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
Cytokinetics, Inc. (NASDAQ: CYTK) announced today that abstracts summarizing non-clinical data relating to GSK-923295, an inhibitor of centromere-associated protein E (CENP-E), were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held November 15-19, 2009 in Boston, Massachusetts.
GSK-923295 is currently being studied in a Phase I, first time in humans clinical trial sponsored by GlaxoSmithKline and designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of this novel drug candidate in patients with solid tumors.
Related Categories
Corporate NewsStocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
